{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dimethyl+fumarate+%28DMF%29",
    "query": {
      "intervention": "dimethyl fumarate (DMF)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 62,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dimethyl+fumarate+%28DMF%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T02:11:51.296Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02410200",
      "title": "Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 22,
      "start_date": "2015-09-30",
      "completion_date": "2016-09-23",
      "has_results": true,
      "last_update_posted_date": "2017-10-23",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 1,
      "location_summary": "San Bernardino, California",
      "locations": [
        {
          "city": "San Bernardino",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02410200"
    },
    {
      "nct_id": "NCT07757568",
      "title": "Prospective Evaluation of De-Escalation From antiCD-20 Therapies to Dimethyl Fumarate (Tecfidera) or Diroximel Fumarate (Vumerity)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis (MS) Relapsing Remitting"
      ],
      "interventions": [
        {
          "name": "Vumerity",
          "type": "DRUG"
        },
        {
          "name": "Tecfidera",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2023-03-07",
      "completion_date": "2026-11-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07757568"
    },
    {
      "nct_id": "NCT03870763",
      "title": "Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Dimethyl Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon Beta-1a",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 11,
      "start_date": "2019-03-19",
      "completion_date": "2022-07-21",
      "has_results": true,
      "last_update_posted_date": "2023-06-15",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 1,
      "location_summary": "Raleigh, North Carolina",
      "locations": [
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03870763"
    },
    {
      "nct_id": "NCT02337426",
      "title": "Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Brain Glioblastoma",
        "Adult Giant Cell Glioblastoma",
        "Adult Gliosarcoma"
      ],
      "interventions": [
        {
          "name": "Dimethyl Fumarate",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2015-02-13",
      "completion_date": "2017-11-09",
      "has_results": false,
      "last_update_posted_date": "2019-06-28",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02337426"
    },
    {
      "nct_id": "NCT02675413",
      "title": "Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Dimethyl Fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-04",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2016-07-20",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 2,
      "location_summary": "St Louis, Missouri • Seattle, Washington",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02675413"
    },
    {
      "nct_id": "NCT05576779",
      "title": "Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ofatunumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 2101,
      "start_date": "2020-12-03",
      "completion_date": "2021-12-31",
      "has_results": false,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05576779"
    },
    {
      "nct_id": "NCT00451451",
      "title": "Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "BG00012",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Glatiramer Acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1417,
      "start_date": "2007-06",
      "completion_date": "2011-08",
      "has_results": true,
      "last_update_posted_date": "2015-01-26",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 72,
      "location_summary": "Birmingham, Alabama • Cullman, Alabama • Huntsville, Alabama + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00451451"
    },
    {
      "nct_id": "NCT04834401",
      "title": "Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Sclerosis",
        "Covid19"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "St. Barnabas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 45,
      "start_date": "2021-03-22",
      "completion_date": "2022-05-17",
      "has_results": false,
      "last_update_posted_date": "2022-08-18",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 1,
      "location_summary": "Livingston, New Jersey",
      "locations": [
        {
          "city": "Livingston",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04834401"
    },
    {
      "nct_id": "NCT02907177",
      "title": "Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ponesimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Actelion",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 136,
      "start_date": "2017-03-30",
      "completion_date": "2020-03-26",
      "has_results": true,
      "last_update_posted_date": "2021-05-18",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Fresno, California • Pasadena, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Santa Clarita",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02907177"
    },
    {
      "nct_id": "NCT02784834",
      "title": "Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Choi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2016-06",
      "completion_date": "2019-02",
      "has_results": true,
      "last_update_posted_date": "2019-09-19",
      "last_synced_at": "2026-09-23T02:11:51.296Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02784834"
    }
  ]
}